The Brindusa Truta Lab studies inflammatory bowel diseases, specifically Crohn’s disease and ulcerative colitis. Recent studies defined factors associated with the development of Crohn's disease after ileal pouch anal anastomosis; determined the value of histology in identifying Lynch syndrome in early-onset of colorectal cancer patients; and compared the phenotype and genotype in adenomatous polyposis patients with and without a family history.
Investigators in the IBD and Autoimmune Liver Diseases Laboratory conduct basic and translational research in inflammatory bowel disease (IBD) and autoimmune liver diseases. One area of focus is discovering and developing biomarkers for diagnosing and prognosticating IBD and other autoimmune liver diseases (AILDs). We also are exploring the molecular pathogenesis of—and developing novel therapies for—IBD. In addition, we are working to understand the molecular reason why many IBD patients fail to respond to mainstay drug therapies—and to develop diagnostic assays that can predict non-responders before starting them on those therapies. These biomarker studies have led to our application for four U.S. and international patents.